Drug-loaded microspheres are manufactured from LACTEL DL-PL (B6005-2) by an oil-in-water solvent evaporation route using dichloromethane or ethyl acetate as the dispersed phase. The polymer concentration is held between 10 wt% and 20 wt%. The drug substance is either dissolved or suspended in the dispersed phase depending on solubility. A continuous aqueous phase containing 0.5–2.0 wt% poly(vinyl alcohol) at 4–8°C is prepared in a jacketed vessel. The two phases are combined under a rotor-stator homogenizer operating at a tip speed of 10–25 m/s. The resulting oil-in-water emulsion is transferred to a hardening bath containing 10–20 volumes of deionized water at 2–8°C to extract residual solvent. After solvent extraction, the microspheres are collected by filtration, frozen at -40°C, and lyophilized at 0.1 mbar for 24–48 h. The ester-terminated morphology of the polymer reduces the free carboxylic acid end-group population, which lowers initial water uptake rate and delays autocatalytic polymer chain scission during the first 24–72 h of release. In vitro release testing is performed using USP apparatus 4 or a sample-and-separate method in phosphate-buffered saline at 37°C and pH 7.4. Encapsulation efficiency is measured by reversed-phase high-performance liquid chromatography. Residual dichloromethane is controlled according to USP <467>, while ethyl acetate is evaluated under International Council for Harmonisation Q3C. Particle size distribution is measured by laser diffraction according to ISO 13320:2020, with a typical D50 target of 20–80 µm for intramuscular or subcutaneous administration. Terminal products include injectable suspensions for extended-release peptide and small-molecule delivery, where the polylactide matrix controls release by bulk erosion rather than surface erosion.

What Governs Molecular Weight Retention in Injection-Molded Fracture Fixation Stock?

Injection molding of this ester-terminated poly(D,L-lactide) requires pre-drying to a residual moisture level below 0.025 wt% (250 ppm) because the ester backbone is hydrolytically labile at melt temperature. The dryer set point is commonly 60–80°C with a dew point of -40°C or drier for 4–8 h. The injection barrel is configured in three zones, feed at 150°C, compression at 170°C, and nozzle at 180°C. Melt temperature above 190°C accelerates lactide reformation and reduces number-average molecular weight. Published degradation data for amorphous poly(D,L-lactide) indicate that holding at 200°C for 10 min can reduce number-average molecular weight by 10–20%. Residence time is therefore limited to less than 10 min. The mold is held at 20–30°C to allow rapid solidification without crystalline domain formation. Clamp force for small orthopaedic implant molds is typically 150–500 kN depending on projected area. Melt flow rate is measured according to ISO 1133-1:2022 at 190°C under 2.16 kg. Tensile specimens are conditioned at 23°C and 50% RH for 48 h before testing per ASTM D638-14. In vitro degradation is evaluated according to ASTM F1635-16 in phosphate-buffered saline at 37°C, with molecular weight and mass retention recorded at 4, 8, and 12 weeks. Terminal products include bioresorbable interference screws, suture anchors, and craniofacial fixation plates, where load-bearing duration is limited by the amorphous polymer’s strength decay profile under physiological hydrolysis.

A low-lactide-content coating vehicle is prepared by dissolving LACTEL DL-PL (B6005-2) in anhydrous acetone or ethyl acetate at 1–3% w/v. The solution is filtered through a 0.2 µm polytetrafluoroethylene membrane to remove insoluble particulates before coating. Ultrasonic spray nozzles operating at 40–120 kHz with a power of 1–5 W are used to deposit the polymer onto metallic implant surfaces. Flow rate is held at 0.1–0.5 mL/min, and the substrate temperature is maintained at 40–60°C to control solvent flash-off and coating uniformity. Coating thickness is bounded at 1–10 µm per layer, with successive passes used when a thicker barrier is required. For drug-eluting coatings, drug-to-polymer ratios are restricted to 1:1 to 1:5 to maintain film continuity above the glass transition temperature of the amorphous polyester. Hemocompatibility is evaluated according to ISO 10993-4:2017, and cytotoxicity is assessed by ISO 10993-5:2009. Particulate matter control follows USP <788> for injectable components. Terminal products include bioresorbable topcoats for cardiovascular stents, orthopaedic implant coatings, and microcatheter hydrophilic-lubricious base layers where degradation must occur without generating acidic byproducts at the tissue interface.

Electrospun Microfibrous Matrix Formation Under Static and Dynamic Culture

Electrospinning of this polymer is performed from a limited set of solvents because the amorphous poly(D,L-lactide) requires a low-boiling, high-dielectric system for stable jet formation. The polymer is dissolved in 1,1,1,3,3,3-hexafluoroisopropanol at 6–12 wt%, or in a chloroform/dimethylformamide blend at 3:1 volume ratio with total polymer loading of 8–14 wt%. The solution is delivered through a 22G blunt-tip needle at 0.5–2.0 mL/h. Applied voltage is set between 15 kV and 25 kV, and the tip-to-collector distance is maintained at 10–20 cm. A rotating drum collector at 200–800 rpm is used to induce fiber alignment. Fiber diameter is measured by scanning electron microscopy with image analysis of at least 100 fibers per lot. Scaffold pore size distribution is measured by mercury intrusion porosimetry according to ASTM D4404-18. Cytotoxicity is assessed according to ISO 10993-5:2009, and extraction conditions follow ISO 10993-12:2021. Terminal products include vascular graft matrices, peripheral nerve conduits, and dermal regeneration templates where the electrospun mat provides cell infiltration channels and resorbs over a period of 6–18 months under physiological conditions.

If Heat Exposure Exceeds 130°C During Drying, What Changes in Degradation Rate?

Drying of LACTEL DL-PL (B6005-2) is a critical step because the ester-terminated backbone undergoes thermal chain scission at elevated temperatures even in the absence of moisture. If the dryer set point exceeds 130°C, the number-average molecular weight declines within 2–4 h due to random chain scission and lactide reformation, independent of residual water. The acceptable drying window for melt processing is 60–80°C for 4–8 h under a dew point of -40°C or drier. Residual moisture is confirmed by Karl Fischer titration according to USP <921>. Extrusion of filament for additive manufacturing uses a single-screw extruder with an L/D ratio of 24:1 and compression ratio of 2.5:1. Barrel zones are set at 160°C, 170°C, and 180°C, with melt temperature measured by an infrared probe at 170–185°C. Diameter is controlled to 1.75 mm ± 0.05 mm using a laser micrometer, and roundness is maintained by a closed-loop haul-off with tension control. Thermal transition verification is performed by differential scanning calorimetry according to ASTM D3418-21. The terminal product is filament feed for fused filament fabrication of bioresorbable surgical templates, where dimensional stability during storage depends on residual moisture below 0.025 wt%.

Barrier films are cast from a solution of LACTEL DL-PL (B6005-2) in methylene chloride or chloroform at 5–15 wt%. The solution is applied to a glass substrate using a doctor blade with a gap of 200–800 µm. Drying is performed at 40°C under vacuum for 12–24 h, followed by a nitrogen-purge step to reduce residual solvent below USP <467> limits. Final film thickness is controlled between 10 µm and 50 µm. Tensile properties are measured according to ASTM D882-18 at a crosshead speed of 10 mm/min. Tear resistance is evaluated by ASTM D1938-09, and flexural fatigue is screened by repeated crease testing using a custom fixture. Sterilization by ethylene oxide is validated according to ISO 11135:2014, with ethylene oxide residue limits per ISO 10993-7:2008. Terminal products include post-surgical adhesion barrier films and guided tissue regeneration membranes, where the amorphous polyester film must remain flexible through the wound-healing phase without failing under suture tension.

Thermal Degradation Pathways and Filament Dimensional Control in Additive Manufacturing Stock

Fused filament fabrication stock produced from this polymer is printed at a nozzle temperature of 180–190°C to stay below the threshold of rapid chain scission. The build plate is set at 20–30°C, and a nozzle diameter of 0.4 mm is used with a layer height of 150 µm. Print speed is limited to 20–40 mm/s to reduce shear-induced molecular weight loss and prevent under-extrusion. Part cooling is set to 30–50% fan speed because amorphous poly(D,L-lactide) solidifies without crystalline lattice development and excessive cooling causes delamination at layer interfaces. Printed scaffolds are annealed at 60°C for 2 h in a forced-air oven to relieve residual stress. Dimensional accuracy is assessed by coordinate measuring machine or structured-light scanning, with geometric tolerance classes assigned under ISO 52921-13. In vitro degradation of printed coupons follows ASTM F1635-16 in phosphate-buffered saline at 37°C. Terminal products include patient-specific maxillofacial scaffolds and cranial bone regeneration templates, where the printed architecture must maintain pore interconnectivity while degrading over a period of 12–24 months.

Melt-Compounding β-Tricalcium Phosphate into Ester-Terminated Poly(D,L-lactide)

Melt compounding of LACTEL DL-PL (B6005-2) with β-tricalcium phosphate is performed on a co-rotating twin-screw extruder with an L/D ratio of 40:1. The polymer feed is introduced at zone 1, and the ceramic filler is side-fed at zone 5 to limit barrel wear and filler attrition. Filler loading is restricted to 10–30 wt% because higher loadings raise melt viscosity and can produce torque excursions above 70% of the extruder drive limit. Screw speed is set at 200–400 rpm, and the melt temperature is maintained at 170–185°C. The extrudate is pelletized under dry nitrogen and dried to <0.025 wt% moisture before injection molding. Dispersion quality is evaluated by ash content according to ISO 3451-1:2019. Tensile modulus and strength are measured per ASTM D638-14 after conditioning at 23°C and 50% RH. Flexural properties are measured according to ISO 178:2019. Published data for melt-compounded B6005-2 with β-tricalcium phosphate above 30 wt% remains limited, so validation lot testing under ISO 10993-6:2016 is required before implant use. Terminal products include bioresorbable osteochondral screws and interference plugs intended for subchondral bone repair, where the ceramic phase modifies degradation pH and provides an osteoconductive surface once the polyester matrix begins to resorb.